ARKG vs VHT

Key Takeaways

• ARKG is an actively managed thematic ETF focused on the genomics revolution, while VHT is a passively managed fund tracking a broad health care index.
• ARK Genomic Revolution ETF (ARKG) maintains a concentrated portfolio of approximately 33 holdings with an expense ratio of 0.75%, emphasizing innovative biotech and genomics companies.
• Vanguard Health Care ETF (VHT) offers broad diversification across more than 420 holdings at a low 0.09% expense ratio, providing exposure to pharmaceuticals, biotechnology, equipment, and services.
• ARKG targets high-growth, smaller-cap genomics innovators with higher volatility potential, whereas VHT delivers lower-cost, market-cap-weighted exposure to established health care leaders.
• Both ETFs provide health care sector exposure but differ significantly in strategy, with ARKG representing active thematic investing and VHT representing passive sector indexing.
• Structural differences in management style, costs, and concentration create distinct risk-return profiles suited to varying investor objectives within the health care space.

Introduction

Investors seeking health care exposure often evaluate thematic and broad-sector exchange-traded funds (ETFs) to balance innovation-driven growth against diversified stability. ARK Genomic Revolution ETF (ARKG) and Vanguard Health Care ETF (VHT) represent two distinct approaches to the same sector. ARKG pursues active management of genomics-focused companies, while VHT delivers passive, comprehensive coverage of the health care industry. These ETFs do not compete directly but offer alternative strategies for investors pursuing sector exposure, with differences in cost, concentration, and thematic emphasis shaping their positioning in current market cycles.

ARK Genomic Revolution ETF (ARKG) Overview

ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund launched in 2014 that seeks long-term capital growth by investing at least 80% of assets in domestic and foreign equity securities tied to the genomics revolution. The strategy focuses on companies advancing gene therapy, bioinformatics, molecular medicine, and related innovations across health care, information technology, and other sectors. The fund typically holds 30 to 40 securities, with recent data showing approximately 33 holdings. Top positions include 10x Genomics Inc. (TXG), Twist Bioscience Corp. (TWST), Tempus AI Inc. (TEM), CRISPR Therapeutics AG (CRSP), and Personalis Inc. (PSNL). Allocations concentrate heavily in biotechnology and life sciences tools, resulting in elevated concentration risk. The expense ratio stands at 0.75%, reflecting active management and thematic research intensity. Rebalancing occurs dynamically based on the advisor’s fundamental and quantitative analysis rather than a fixed index schedule.

Vanguard Health Care ETF (VHT) Overview

Vanguard Health Care ETF (VHT) is a passively managed fund launched in 2004 that seeks to track the performance of the MSCI US Investable Market Health Care 25/50 Index. The index provides multicapitalization exposure to U.S. health care companies classified under the Global Industry Classification Standard (GICS). The ETF employs a full-replication strategy when feasible and holds approximately 420 stocks. Top holdings typically feature Eli Lilly & Co. (LLY), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), UnitedHealth Group Inc. (UNH), and Merck & Co. Inc. (MRK). Sector allocations span pharmaceuticals, biotechnology, health care equipment, life sciences tools, managed care, and services. The expense ratio is 0.09%, consistent with Vanguard’s low-cost indexing approach. Quarterly rebalancing aligns holdings with index weightings, promoting broad diversification and lower turnover.

Industry and Thematic Backdrop

The health care sector continues to experience structural growth drivers including aging populations, advances in precision medicine, and expanding biotechnology pipelines. Genomics and gene-editing technologies represent a high-conviction subset within the broader sector, attracting research and development capital amid regulatory progress on novel therapies. Macroeconomic factors such as interest rate expectations influence capital allocation between high-growth innovators and established pharmaceutical and managed-care companies. Regulatory developments around drug pricing and approval pathways affect both subsegments, while capital flows into health care remain supported by long-term demographic trends. Sector risks include policy uncertainty, clinical trial outcomes, and competition for innovation leadership.

Performance and Positioning Comparison

In recent market cycles, ARK Genomic Revolution ETF (ARKG) has exhibited higher volatility tied to its concentrated exposure to early-stage genomics companies and sensitivity to sentiment around breakthrough technologies. Vanguard Health Care ETF (VHT) has delivered more stable returns consistent with broad sector benchmarks, benefiting from the scale and earnings consistency of large-cap pharmaceutical and managed-care holdings. During periods of sector rotation favoring established health care names, VHT’s diversified profile has provided relative resilience. ARKG’s active thematic approach positions it for potential outperformance in environments where genomics innovation accelerates, though its smaller-cap tilt introduces greater drawdown risk. Relative positioning reflects trade-offs between growth potential and defensive sector characteristics across varying macroeconomic conditions.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening.

Tickeron AI Verdict

Based on observable structural factors, Tickeron’s AI would currently assign a higher probability of favorability to Vanguard Health Care ETF (VHT). Its significantly lower expense ratio, broad diversification across hundreds of holdings, and passive replication of a comprehensive health care index provide cost efficiency and reduced concentration risk. While ARK Genomic Revolution ETF (ARKG) offers differentiated thematic exposure to genomics innovation, its higher costs and narrower holdings profile introduce greater structural variability in trend consistency and risk exposure.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations